BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND CRTC1, Q6UUV9, 23373, ENSG00000105662, KIAA0616, TORC1, MECT1, WAMTP1, FLJ14027 AND Treatment
7 results:

  • 1. Phase 1 study of mtorc1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
    Voss MH; Gordon MS; Mita M; Rini B; Makker V; Macarulla T; Smith DC; Cervantes A; Puzanov I; Pili R; Wang D; Jalal S; Pant S; Patel MR; Neuwirth RL; Enke A; Shou Y; Sedarati F; Faller DV; Burris HA
    Br J Cancer; 2020 Nov; 123(11):1590-1598. PubMed ID: 32913286
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. New agents and new targets for renal cell carcinoma.
    Philips GK; Atkins MB
    Am Soc Clin Oncol Educ Book; 2014; ():e222-7. PubMed ID: 24857106
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
    Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
    Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
    Armstrong AJ; George DJ; Halabi S
    J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Therapy for non-clear cell histologies in renal cancer.
    Bitting RL; Madden J; Armstrong AJ
    Curr Clin Pharmacol; 2011 Aug; 6(3):169-80. PubMed ID: 21861801
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.
    Cho DC; Cohen MB; Panka DJ; Collins M; Ghebremichael M; Atkins MB; Signoretti S; Mier JW
    Clin Cancer Res; 2010 Jul; 16(14):3628-38. PubMed ID: 20606035
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
    Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
    Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.